NEW YORK (GenomeWeb News) – PGXL Technologies today said that it has been awarded a $300,000 contract from the National Cancer Institute to advance research directed at circulating tumor cells for the early detection of cancer.
The Louisville, Ky.-based firm, a sister company to PGXL Laboratories, uses a technology called DEPArray, developed by Silicon Biosystems. The two firms said in April they were collaborating to make the technology available through PGXL.
The DEPArray technology is based on dielectrophoresis for isolating and manipulating cells in a suspension matrix and can be used to investigate the underlying causes of disease, disease progression, and the basis of drug resistance and efficacy.
PGXL said today that it and Silicon Biosystems are developing a method to identify and isolate CTCs "that are invisible to conventional technology." Kevin Goudy heads the PGXL team that will carry out the work on the NCI contract, which is one of four awarded by the institute to expand the types of detectable CTCs.